Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Philippe Moreau, Brian G.M. Durie et al.|Journal of Clinical Oncology|2015Cited by 2.2k
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted MyelomaMarco Ladetto, Antonio Palumbo, G Pagliano et al.|Journal of Clinical Oncology|2010Cited by 268
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Antonio Palumbo, Alessandra Larocca et al.|Blood|2011Cited by 268
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalSimone Ferrero, Antonio Palumbo, Marco Ladetto et al.|Leukemia|2014Cited by 83